Quick Dispatch:
Your soul trial oral semaglutide cardiovascular outcomes results 2024 nejm Oral Semaglutide in High-Risk Type 2 Diabetes: Cardiovascular Benefit Confirmed in the SOUL Trial orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your soul trial oral semaglutide cardiovascular outcomes results 2024 nejm Oral Semaglutide in High-Risk Type 2 Diabetes: Cardiovascular Benefit Confirmed in the SOUL Trial ships.
Need Help?
Questions about soul trial oral semaglutide cardiovascular outcomes results 2024 nejm Oral Semaglutide in High-Risk Type 2 Diabetes: Cardiovascular Benefit Confirmed in the SOUL Trial, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for soul trial oral semaglutide cardiovascular outcomes results 2024 nejm Oral Semaglutide in High-Risk Type 2 Diabetes: Cardiovascular Benefit Confirmed in the SOUL Trial in your area.
💥Soul study group recently shared the result of their study :✔️ Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes @NEJM 🟡 n=9650 🟡 42.4 %had history of CKD 🟡 Majority
28.93
Trial Scorecard: SOUL
22.75
New Science Suggests Semaglutide Improves CV Outcomes Beyond Weight Loss
29.01
Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial
25.03
VisualAbstract: Semaglutide Improves Outcomes in Patients with Obesity-Related Heart Failure and Type 2 Diabetes
20.70
Heart disease is the #1 cause of death in type 2 diabetes — and for the first time, an oral GLP-1 drug has been proven to reduce major cardiovascular events The SOUL
26.65
Oral semaglutide found to lower risk of heart failure events in people with type 2 diabetes
20.88
